Through rigorous value chain analysis and legal scenario planning, we are laying the foundation for successful opportunistic investment in the rapidly approaching industry of legalized psychedelics. Join us.
A number of psychedelic compounds show high promise of legalization in the near future, due to the beneficial effects they have for individuals with PTSD, depression, anxiety, and addiction.
The specific regulations adopted in the legalization of these substances, and whether they are legalized for medical use, recreational use, or both, will have substantial impacts on the value chain in the industry, and create unique opportunities for investment in each case. We are creating the foundation to allow you to capture the first mover when these opportunities arise.
Some of these substances are already in phase 3 clinical trials, or have legalization ballots in state elections. The time for investment is rapidly approaching for a number of these substances, and we will be prepared to act when the time comes.
Our capital deployment strategy is founded on basic principles of value chain analysis. Each state will have a unique distribution of regulatory barriers and market incentives that will create specific opportunities for value capture. We work alongside our advisory board to identify and plan for each of these contingencies.
The psychoactive properties of ketamine, a dopaminergic compound, are hypothesized to be mediated by N-methyl-D-aspartate receptor (NMDAR) inhibition. This inhibition is thought to contribute both to sustained strengthening of excitatory synapses, as well as increased dopamine levels in the frontal cortex and striatum.
Ketamine is expected to be of particular medical benefit in cases of treatment-resistant depression. A single dose of ketamine has been shown to reduce suicide thoughts for a considerable period post-treatment, and is therefore being investigated as a mood stabilizer for those at risk of suicide.
Psilocybin, a 5-HT2A receptor agonist, is hypothesized to exert its psychoactive effects by activation of 5-HT2A receptors, similar to LSD.
It has been shown to produce a significant reduction in anxiety and depression and alleviate the demoralization and hopelessness experienced by patients suffering from terminal cancer, improving their spiritual well-being and quality of life. In addition, it has been shown to be useful in the treatment of both alcohol and tobacco dependence.
MDMA has been shown to enhance the release serotonin, norepinephrine, dopamine and oxytocin.
These effects result in a dynamic modulation of emotional memory circuits, which increase self-compassion, feelings of connectedness, and allow for reprocessing of traumatic memories and greater levels of emotional engagement with therapeutic processes. Trials have shown a 66.2% success rate of patients with PTSD overcoming their symptoms, with adverse affects at practically negligible levels.
The psychosensory effects of LSD, a 5-HT2A receptor agonist, are hypothesized to be mediated by activation of 5-HT2A receptors.
One of the first psychedelics to be clinically investigated, the first studies being conducted in the 1950’s, it has shown promising results in clinical trials in the treatment of anxiety, addiction and depression and is hypothesized to be of potential use in the treatment of chronic pain.
If you're looking to find out more about our work, are interested in becoming a LP, or want to contribute to our cause then please reach out to firstname.lastname@example.org. Building a community around this movement is the only way we'll be able to destigmatize these medicines and create a wider variety of opportunities for struggling individuals to address their mental health. Thank you.